50 research outputs found
Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients
The re-emergence of Zika virus (ZIKV) caused widespread infections that were linked to Guillain-Barré syndrome in adults and congenital malformation in fetuses, and epidemiological data suggest that ZIKV infection can induce protective antibody responses. A more detailed understanding of anti-ZIKV antibody responses may lead to enhanced antibody discovery and improved vaccine designs against ZIKV and related flaviviruses. Here, we applied recently-invented library-scale antibody screening technologies to determine comprehensive functional molecular and genetic profiles of naturally elicited human anti-ZIKV antibodies in three convalescent individuals. We leveraged natively paired antibody yeast display and NGS to predict antibody cross-reactivities and coarse-grain antibody affinities, to perform in-depth immune profiling of IgM, IgG, and IgA antibody repertoires in peripheral blood, and to reveal virus maturation state-dependent antibody interactions. Repertoire-scale comparison of ZIKV VLP-specific and non-specific antibodies in the same individuals also showed that mean antibody somatic hypermutation levels were substantially influenced by donor-intrinsic characteristics. These data provide insights into antiviral antibody responses to ZIKV disease and outline systems-level strategies to track human antibody immune responses to emergent viral infections
Randomization to standard and concise informed consent forms: Development of evidence-based consent practices
A DNA Vaccine for Ebola Virus Is Safe and Immunogenic in a Phase I Clinical Trial
Ebola viruses represent a class of filoviruses that causes severe hemorrhagic fever with high mortality. Recognized first in 1976 in the Democratic Republic of Congo, outbreaks continue to occur in equatorial Africa. A safe and effective Ebola virus vaccine is needed because of its continued emergence and its potential for use for biodefense. We report the safety and immunogenicity of an Ebola virus vaccine in its first phase I human study. A three-plasmid DNA vaccine encoding the envelope glycoproteins (GP) from the Zaire and Sudan/Gulu species as well as the nucleoprotein was evaluated in a randomized, placebo-controlled, double-blinded, dose escalation study. Healthy adults, ages 18 to 44 years, were randomized to receive three injections of vaccine at 2 mg (n = 5), 4 mg (n = 8), or 8 mg (n = 8) or placebo (n = 6). Immunogenicity was assessed by enzyme-linked immunosorbent assay (ELISA), immunoprecipitation-Western blotting, intracellular cytokine staining (ICS), and enzyme-linked immunospot assay. The vaccine was well-tolerated, with no significant adverse events or coagulation abnormalities. Specific antibody responses to at least one of the three antigens encoded by the vaccine as assessed by ELISA and CD4(+) T-cell GP-specific responses as assessed by ICS were detected in 20/20 vaccinees. CD8(+) T-cell GP-specific responses were detected by ICS assay in 6/20 vaccinees. This Ebola virus DNA vaccine was safe and immunogenic in humans. Further assessment of the DNA platform alone and in combination with replication-defective adenoviral vector vaccines, in concert with challenge and immune data from nonhuman primates, will facilitate evaluation and potential licensure of an Ebola virus vaccine under the Animal Rule
DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
<div><p>Background</p><p>DNA vaccine immunogenicity has been limited by inefficient delivery. Needle-free delivery of DNA using a CO<sub>2</sub>-powered Biojector® device was compared to delivery by needle and syringe and evaluated for safety and immunogenicity.</p><p>Methods</p><p>Forty adults, 18–50 years, were randomly assigned to intramuscular (IM) vaccinations with DNA vaccine, VRC-HIVDNA016-00-VP, (weeks 0, 4, 8) by Biojector® 2000™ or needle and syringe (N/S) and boosted IM at week 24 with VRC-HIVADV014-00-VP (rAd5) with N/S at 10<sup>10</sup> or 10<sup>11</sup> particle units (PU). Equal numbers per assigned schedule had low (≤500) or high (>500) reciprocal titers of preexisting Ad5 neutralizing antibody.</p><p>Results</p><p>120 DNA and 39 rAd5 injections were given; 36 subjects completed follow-up research sample collections. IFN-γ ELISpot response rates were 17/19 (89%) for Biojector® and 13/17 (76%) for N/S delivery at Week 28 (4 weeks post rAd5 boost). The magnitude of ELISpot response was about 3-fold higher in Biojector® compared to N/S groups. Similar effects on response rates and magnitude were observed for CD8+, but not CD4+ T-cell responses by ICS. Env-specific antibody responses were about 10-fold higher in Biojector-primed subjects.</p><p>Conclusions</p><p>DNA vaccination by Biojector® was well-tolerated and compared to needle injection, primed for greater IFN-γ ELISpot, CD8+ T-cell, and antibody responses after rAd5 boosting.</p><p>Trial Registration</p><p>ClinicalTrials.gov <a href="http://clinicaltrials.gov/ct2/show/NCT00109629" target="_blank">NCT00109629</a></p></div
ELISpot responses among the different groups after priming with vaccine and route indicated on X-axis (panel A) and after rAd5 boosting IM (panel B).
<p>The numbers above each boxplot represent the fraction of participants in each group with available data at that time point who were judged to be responders using predefined criteria. The responders are represented on the plot with red dots, and are used to construct the boxplots; blue points represent non-responders and are not included in the boxplots.</p
Maximum Local Reactogenicity Summary for All Vaccinations.
<p>Maximum Local Reactogenicity Summary for All Vaccinations.</p
Vaccine-Induced Sero-Positivity/Sero-Reactivity (VISP/R) through Study Week 42.
<p>Results are counted as positive (or reactive) if these were the results at any time from after first vaccination through study week 42.</p>*<p>Western blot (WB) was done only if the EIA was positive (reactive). HIV-uninfected status was confirmed by negative RNA PCR.</p
Baseline Characteristics of Participants.
<p>Baseline Characteristics of Participants.</p
Frequency of Vaccine-Induced Seropositivity/Reactivity Through Study Week 42.
<p>Subjects were tested at weeks 12, 30 and 42 regardless of the number of vaccines completed. This shows frequency of a “reactive EIA” using a commercial diagnostic kit (Abbott HIV-1/HIV-2 rDNA) at any time during the study. Western blot was performed only for samples with positive EIA. HIV uninfected status was confirmed by RNA PCR tests, which were consistently negative for all subjects throughout the study.</p
Worst Severity of Local Reactogenicity Following DNA and rAd5 Vaccinations.
<p>Worst Severity of Local Reactogenicity Following DNA and rAd5 Vaccinations.</p